Disseminated Histoplasmosis in a Patient With Multiple Sclerosis Treated With Fingolimod

Aleksandra A. Abrahamowicz, MD,* Eric J. Chow, MD, MS, MPH,* Daniel D. Child, MD, PhD, Alexander Dao, MD, Elizabeth D. Morrison, MD, Sharon K. Gill, MD, David M. Rogers, MD, and Kanishka Garvin, MD

Neurol Neuroimmunol Neuroinflamm 2021;8:e966. doi:10.1212/NXI.0000000000000966

Histoplasma capsulatum is an endemic dimorphic fungus found in the central and eastern parts of the United States, leading to infection when conidia from soil or dust contaminated with bird or bat droppings are inhaled.1 Histoplasmosis can result in disseminated infection, with the gastrointestinal tract being a common site.2 We describe a case of histoplasmosis in a patient with multiple sclerosis (MS) on immunomodulatory therapy presenting with gastrointestinal disease.

Case

The patient is a 46-year-old man with relapsing-remitting MS who presented with 3 weeks of fevers, night sweats, and unintentional 20-lbs weight loss without any respiratory symptoms. He described nonbloody stool caliber changes. Outpatient laboratory findings include an elevated alkaline phosphatase 540 U/L (reference range 45–129) that was normal 5 months previous and a positive fecal immunochemical test. He was originally diagnosed with MS in December 2017 after an acute onset left-sided hemisensory loss and an MRI showing involvement of brain and cervical spine with a negative infectious and autoimmune workup. Since his diagnosis in 2017, he had been well controlled on fingolimod, a sphingosine-1-phosphate receptor agonist, with only mild sensory deficits in his left hand and an expanded disability status scale of 1. He has not used other immunosuppressive medications. He is a military veteran with deployments to Afghanistan, Iraq, and countries in Africa and the Pacific Rim with no travel since 2017. He had no other high-risk behaviors or exposures.

At admission, he was afebrile with normal vital signs and only demonstrated moderate right upper quadrant abdominal tenderness. He had a mildly elevated alanine transaminase (ALT) 69 U/L (reference: 0–37) and aspartate aminotransferase (AST) 57 U/L (reference: 0–39). Other laboratory tests included alkaline phosphatase at 607 U/L, total bilirubin 1.5 mg/dL (reference 0.1–1.0), and white blood cell count of 4.3 K/µL (reference 4.3–10). CT and magnetic resonance cholangiopancreatography revealed gallbladder wall thickening and heterogeneous liver parenchyma.

He continued to experience nightly fevers up to 38.4°C. Repeated blood cultures showed no bacterial growth. HIV and hepatitis tests were negative. A colonoscopy showed innumerable sessile lesions ranging from 3 to 8 mm in size (figure e-1, links.lww.com/NXI/A419), biopsies of which were sent to pathology. A liver biopsy was also obtained on hospital day 4. Histopathologic evaluation of the colonic mucosa demonstrated marked lamina propria histiocytosis with severely disrupted crypt architecture. Individual histiocytes had a high burden of intracellular organisms with thick, ovoid cell walls, consistent with a fungal species (figure 1A). The liver core biopsies contained multiple caseating granulomas (figure 1B) replete with yeast...

*These authors contributed equally to this work.
laden histiocytes identical to those observed in the colon (figure 1C). Grocott methenamine silver stain highlighted the cell walls of the intracellular species within the hepatic granulomas (figure 1D). Chronic inflammatory infiltrate was present in biopsies from both sites, but neutrophilic and eosinophilic inflammation was absent. Molecular testing diagnosed \textit{H. capsulatum}. On further questioning on hospital day 7, the patient noted that he was renovating a barn in Michigan in which he had encountered dead bats and rodents.

The patient was treated with liposomal amphotericin B at 4 mg/kg daily. Because of increasing alkaline phosphatase and increasing AST and ALT, itraconazole 200 mg twice daily replacing amphotericin on day 6 of therapy was administered with plans to complete at least 1 year of therapy.

**Discussion**

Our case highlights the morbidity associated with delayed recognition of disseminated histoplasmosis in an immunocompromised patient. Histoplasmosis commonly causes fever, fatigue, and weight loss and a diagnosis should be considered in individuals with risk factors. This patient’s MS had been treated with fingolimod which leads to lymphocyte sequestration in lymph nodes.\cite{3} Fingolimod has been associated with fungal infections including one patient with primary cutaneous histoplasmosis.\cite{4}

Gastrointestinal histoplasmosis without pulmonary symptoms is rare and usually presents with abdominal pain, melena, diarrhea, and bowel obstruction.\cite{5} Cases of \textit{H. capsulatum} with granulomatous hepatitis and associated cholestasis include findings of jaundice and elevated alkaline phosphatase.\cite{5,6} Rapid diagnosis of histoplasmosis can be achieved by serum and urine enzyme immunoassay antigen testing. Immunodiffusion and complement fixation serologic testing are also available, but they may be less sensitive in immunocompromised individuals. The gold standard for identification of \textit{H. capsulatum} is by isolation of organisms through culture or microbiologic stains.\cite{1}

Treatment for disseminated histoplasmosis should be initiated promptly because the disease is almost entirely fatal within 3 months.\cite{1} Liposomal amphotericin B is recommended as first-line therapy in those with severe disease with a transition to itraconazole after 1–2 weeks of amphotericin to complete 12 months of therapy.\cite{7} For immunocompromised patients, lifelong suppressive antifungal therapy may be required if immunosuppression is expected to persist.\cite{7}

This case highlights the importance of considering histoplasmosis in patients with MS on immunomodulatory therapy and exposure risk factors because gastrointestinal histoplasmosis can mimic malignancy in the absence of pulmonary disease. Prompt diagnosis and early treatment are vital because disseminated histoplasmosis is ultimately fatal without treatment.

**Study Funding**

No targeted funding reported.

**Disclosure**

Disclosures available: Neurology.org/NN.

**Publication History**

Received by \textit{Neurology: Neuroimmunology & Neuroinflammation} November 24, 2020. Accepted in final form January 8, 2021.
Appendix Authors

<table>
<thead>
<tr>
<th>Name</th>
<th>Location</th>
<th>Contribution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aleksandra A. Abrahamowicz, MD</td>
<td>Department of Medicine, University of Washington, Seattle</td>
<td>Drafting/revision of the manuscript for content, including medical writing for content, and major role in the acquisition of data</td>
</tr>
<tr>
<td>Eric J. Chow, MD, MS, MPH</td>
<td>Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle</td>
<td>Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data; and study concept or design</td>
</tr>
<tr>
<td>Daniel D. Child, MD, PhD</td>
<td>Department of Laboratory Medicine and Pathology, University of Washington, Seattle</td>
<td>Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data; and study concept or design</td>
</tr>
<tr>
<td>Alexander Dao, MD</td>
<td>Division of Gastroenterology, Department of Medicine, University of Washington, Seattle</td>
<td>Drafting/revision of the manuscript for content, including medical writing for content</td>
</tr>
<tr>
<td>Elizabeth D. Morrison, MD</td>
<td>Gastroenterology, VA Puget Sound Health Care System, Seattle, WA</td>
<td>Drafting/revision of the manuscript for content, including medical writing for content</td>
</tr>
<tr>
<td>Sharon K. Gill, MD</td>
<td>General Medicine Service, VA Puget Sound Health Care System, Seattle, WA</td>
<td>Drafting/revision of the manuscript for content, including medical writing for content and major role in the acquisition of data</td>
</tr>
</tbody>
</table>

Appendix (continued)

<table>
<thead>
<tr>
<th>Name</th>
<th>Location</th>
<th>Contribution</th>
</tr>
</thead>
<tbody>
<tr>
<td>David M. Rogers, MD</td>
<td>Pathology and Laboratory Medicine Service, VA Puget Sound Health Care System, Seattle, WA</td>
<td>Drafting/revision of the manuscript for content, including medical writing for content</td>
</tr>
<tr>
<td>Kanishka Garvin, MD</td>
<td>Allergy and Infectious Diseases, VA Puget Sound Health Care System, Seattle, WA</td>
<td>Drafting/revision of the manuscript for content; major role in the acquisition of data; and study concept or design</td>
</tr>
</tbody>
</table>

References

Disseminated Histoplasmosis in a Patient With Multiple Sclerosis Treated With Fingolimod
*Neurol Neuroimmunol Neuroinflamm* 2021;8;
DOI 10.1212/NXI.0000000000000966

This information is current as of February 18, 2021